Amanda Pacheco

Cooley advised Avenzo Therapeutics, a clinical-stage biotechnology company developing next-generation oncology therapies, on its exclusive license agreement with Duality Biotherapeutics (DualityBio), pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418– a potential best-in-class epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 3 (HER3) bispecific antibody-drug conjugate (ADC) – globally (excluding Greater China). 

Cooley advised H1, a global healthcare data technology company, on its acquisition of Ribbon Health.

Cooley advised Brigit, a financial health technology company, on its definitive agreement to be acquired by Upbound Group (Nasdaq: UPBD), a technology- and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, for total consideration of up to $460 million.

Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept.

Cooley advised Flare Therapeutics, a clinical-stage biotechnology company, on its strategic discovery collaboration with Roche.